Navigation Links
Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Date:8/20/2008

l Market.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.

Forward-Looking Statements

In order to provide our investors with an understanding of our current condition and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements related to our ability to regain compliance with the listing standards of The NASDAQ Global Market or obtain listing on The NASDAQ Capital Market. Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does no
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
2. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
3. Oncothyreon to receive milestone payment
4. Oncothyreon Reports First Quarter 2008 Financial Results
5. Oncothyreon files investigational new drug application for PX-866 oncology compound
6. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
7. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
8. Oncothyreon announces effectiveness of shelf registration statement
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon to present at upcoming investment conferences
11. Oncothyreon reports full year and fourth quarter 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... Sept. 19, 2014 Pfenex Inc. (NYSE MKT: ... of high-value and difficult to manufacture proteins including biosimilar ... the 21 st Annual NewsMakers in the Biotech ... Bertrand Liang , chief executive officer of Pfenex, ... and business strategy on Friday, September 26, 2014 at ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... DUBLIN and PHILADELPHIA , July 8, 2010 ... global specialty biopharmaceutical company,announces that its subsidiaries Shire Development Inc. ... U.S. District,Court for the District of Delaware against ... ( USA ), Inc. (collectively,"Zydus") for the infringement of U.S. ...
... , CHICAGO , July 8 Advanced Life ... in the discovery, development and commercialization of novel drugs in the ... results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) ... a hospital setting. , , ...
... ... ... Oxford Performance Materials (OPM) is very pleased to announce that the firm’s OXPEKK-IG long-term ... KFDA approved the Viking interspinous spinal device made by OPM’s customer Sintea Plustek., , ...
Cached Biology Technology:Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. 2Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 2Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 4OXPEKK-IG Device Viking Gains Regulatory Approval in Korea 2OXPEKK-IG Device Viking Gains Regulatory Approval in Korea 3
(Date:9/19/2014)... a newly discovered hadrosaur with a truly ... Rhinorex condrupus by paleontologists from North Carolina ... what is now Utah approximately 75 million years ... which translates roughly into "King Nose," was a ... hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are usually ...
(Date:9/19/2014)... of years has adapted to the arctic cold, and then ... dangerous for you. , This is happening to the small ... substance, called nonylphenol, comes from the use of certain detergents, ... endocrine disruptor, but when entering the worm it has another ... cells in its body from cold damage. , Enchytraeus ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:Using magnets to help prevent heart attacks 2Optimum tax on foreign fishing in Africa protects stocks and domestic fishing 2Jellyfish blooms shunt food energy from fish to bacteria 2Jellyfish blooms shunt food energy from fish to bacteria 3